|
Patient (age at the time of surgery) | Oncotype DX RS | Operation | Pathology | Adjuvant treatment | Recurrence |
|
Patient 1 (40 years) | 7 low risk | WLE and SLNBx | 13 mm IDC, grade 2, Ki 67 10%, ER 100%, PR 100%, pN0 | Endocrine (ceased after 12 months due to side effects) and radiotherapy | Metastatic disease 7 years after surgery |
Patient 2 (52 years) | 13 intermediate risk | WLE and SLNBx | 15 mm IDC, grade 2, Ki 67 40%, ER 90%, PR 70%, pN0 | Endocrine and radiotherapy | Metastatic disease 5 years after surgery |
Patient 3 (50 years) | 23 intermediate risk | Mastectomy and ALNDx | 18 mm IDC, grade 3, Ki67 20%, ER 90%, PR 80%, pN1 8 mm sentinel node deposit with no extranodal spread | Endocrine | Metastatic disease 3 years after surgery and died in year 4 |
Patient 4 (60 years) | 15 intermediate risk | Mastectomy and SLNB | 50 mm ILC, grade 2, Ki 67 15%, ER 80%, PR 70%, pN1 3 mm sentinel node deposit with extranodal spread | Endocrine and radiotherapy | Metastatic disease 2 years after surgery and died in year 4 |
Patient 5 (65 years) | 35 high risk | WLE and ALNDx | 35 mm IDC, grade 3, Ki 67 49%, ER 90%, PR 0%, pN1 | Chemotherapy, endocrine, and radiotherapy | Metastatic disease 6 years after surgery |
|